

Qualitative evaluation of the use of modelling in resource allocation decisions for HIV and TB

Anna L Bowring (0000-0002-2192-9260)¹, Debra ten Brink¹, Rowan Martin-Hughes¹, Nicole Fraser-Hurt², Nejma Cheikh², Nick Scott¹

¹ Burnet Institute, Melbourne, Australia

² The World Bank, Washington DC, United States of America

Correspondence to Anna Bowring,

anna.bowring@burnet.edu.au

Burnet Institute

85 Commercial Rd,

Melbourne, Victoria, 3004

Australia

Abstract

Introduction: Globally, resources for health spending, including HIV and tuberculosis (TB), are constrained, and a substantial gap exists between spending and estimated needs. Optima is an allocative efficiency modelling tool that has been used since 2010 in over 50 settings to generate evidence for country-level HIV and TB resource allocation decisions. This evaluation sought to assess the determinants and outcomes of using modelling to inform financing priorities from the perspective of country stakeholders and their international partners.

Methods: In October-December 2021, the World Bank and Burnet Institute led 16 small-group virtual interviews with representatives from national governments and international health and funding organizations. Interviewed stakeholders represented nine countries and 11 different disease program country contexts where Optima modelling work had been undertaken. Interview notes were thematically analyzed to evaluate determinants of research translation into policy and practice.

Results: Common factors that facilitated or inhibited the application of Optima findings broadly encompassed the perceived validity of findings, health system financing mechanisms, the extent of stakeholder participation, engagement of funding organization, socio-political context, and whether the analysis was timed to suit data and stakeholder needs. Key reported outcomes of Optima analyses related to improved understanding of data and allocative efficiency, support for strategic planning, financial planning, funding advocacy and grant proposals, and influencing investment shifts between interventions or their delivery modalities.

Conclusion: Allocative efficiency modeling has supported evidence-informed decision making in numerous contexts and enhanced the conceptual and practical understanding of allocative efficiency. Most immediately, greater involvement of country stakeholders in modelling studies and tying the timing of such studies to key strategic and financial planning decisions may increase the impact on decision making. To further improve relevance and acceptance of modelling findings, there needs to be greater consideration given to integrated disease modelling, equity goals, and financing constraints.

Key words: mathematical modelling, health policy, resource allocation, stakeholder participation

What is already known on this topic -

Mathematical modelling is widely used in health planning and policy, including to support understanding of HIV epidemics at national and global levels. Allocative efficiency modelling tools such as Optima are used to consider the most cost-effective distribution of resources to maximise specified health gains. Despite the widespread application of modelling tools, there are limited examples of groups evaluating the translation and adoption of model findings into policy and financing decisions. The available literature prescribes stakeholder engagement as one of the key principles for effective modelling, thus assessing the acceptability and application of modelling implementation with key stakeholders may provide important insight into means to improve the uptake and impact of modelling evidence.

What this study adds -

This evaluation of prior Optima HIV and TB modelling is one of few studies that explores factors influencing the translation of modelling results into policy and practice, with a focus on health financing priorities. Our findings demonstrate that allocative efficiency modeling has supported evidence-informed decision making in numerous contexts, enhanced the conceptual and practical understanding of allocative efficiency and supported constructive dialogue on the data and evidence. We found that key facilitators of translating findings into policy include timing of analyses prior to key strategic and financial planning exercises, confidence in the input data, involvement of diverse stakeholders early and throughout the modelling process, flexible financing mechanisms, and familiarity and understanding of the model.

How this study might affect research, practice or policy -

These findings highlight opportunities to strengthen the local value, acceptance and utility of such analyses for better prioritized spending and ultimately to contribute to improved health outcomes. These findings have relevance to diverse modelling groups to technically support health program and financial planning in international contexts. It provides an overview of facilitators and barriers that can assist teams in conducting more effective and relevant modelling studies for policy makers and other stakeholders. Resulting improvements to processes may help to increase stakeholders' satisfaction with the modelling processes and acceptance of findings, improve the efficiency and use of stakeholders' time, promote increased local ownership of findings, and lead to greater opportunities for developing local capacity in contributing to the modelling processes. Ultimately, these findings may support modelling groups, sponsors, and stakeholders to collaborate, implement and apply modelling effectively to decision making for health spending and strategies.

Introduction

Although countries have made critical gains in reaching global targets towards HIV and tuberculosis (TB) elimination,¹ closing the remaining gap in prevention and treatment targets will require strategic investment.^{2,3} As international HIV investment becomes increasingly constrained, countries are shifting to internal resources to fund their HIV responses. In low- and middle-income countries, the domestic share of HIV funding has increased from 51% in 2010 to 61% in 2020, and total funds available for HIV have been decreasing since 2017.⁴ Similarly for TB, financing gaps to meet end-TB targets have widened since 2016, particularly among low- and-middle income countries.^{2,5,6} Shrinking budget envelopes mean that governments need to make challenging decisions on HIV and TB investments amidst competing health and social priorities, including the ongoing COVID-19 pandemic.⁷

Mathematical modelling has been widely used to project epidemics at national and global levels, with models such as the Spectrum suite used to produce HIV estimates to guide national policy and planning.⁸ Modelling is also recognized as an important tool when there are gaps in empirical data, or to compare the potential impact of different intervention combinations within a theoretical framework. The use of modelling to guide health decisions has burgeoned in recent years, including to guide countries' responses to the COVID-19 pandemic.^{9,10} As well as projecting epidemics under different intervention scenarios, models can be used to inform financial resource allocation. Optima HIV and Optima TB are allocative efficiency models designed to do this. They are dynamic, compartmental population-based models with economic components that can estimate how budgets can be optimally allocated across interventions to maximize progress towards specific objectives or country targets.¹¹⁻¹³ The underlying epidemiology in each model application is calibrated to align with prior nationally accepted estimates and validated with in-country stakeholders. These models have been applied in over 50 countries since 2010 (HIV) and 2016 (TB) in collaboration with the World Bank, international and country partners. However, it has not yet been qualitatively evaluated how these models have influenced policy or financing.

Despite the widespread use of mathematical modelling in health planning and policy, it is rarely evaluated beyond technical methods and direct outputs¹⁴, with limited evaluation of the mechanisms by which model findings and recommendations are adopted by countries into policy and programming.¹⁵⁻¹⁷ Most modelling guidelines focus on technical aspects or results communication¹⁸ and have less emphasis on how to work together with policy and decision makers.^{19,20} However, existing research prescribes stakeholder engagement as one of the key principles for effective modelling,¹⁹ and therefore assessing the use of past modelling analyses by key stakeholders may provide important insight to improve the uptake and impact of future modelling. This evaluation sought to assess the determinants and outcomes of translating modelling research into policy and practice from the perspective of the major consumers of Optima HIV and TB modelling: country stakeholders and their international partners. These findings will provide constructive insights to maximise the relevance, perceived usefulness, and application of modelling results for setting health financing priorities.

Methods

Study overview

This study draws on qualitative data collected as part of an internal feedback and quality assurance (QA) exercise of Optima HIV and TB applications. In October to December 2021, the World Bank and Burnet

Institute invited key stakeholders from countries involved in prior Optima applications to participate in a virtual interview to discuss their experiences and satisfaction with the modelling and engagement processes, how the model findings and recommendations had been used in country, and perceptions on the usefulness and impact of Optima analysis for supporting decision making and addressing evidence gaps. Qualitative enquiry through small group interviews was supplemented with quantitative case studies focusing on changes in spending, program coverage, and modeled epidemic impact. This analysis focuses on the qualitative findings.

Participant selection and description

Study participants were purposively sampled from country stakeholders and international partner organizations who have participated in or sponsored Optima HIV and TB analyses. The research team compiled a list of all previous Optima HIV and TB analyses from 2012 until 2021. Any analyses using model versions prior to 2012 were excluded due to an inability to update the quantitative analysis, and analyses conducted after 2019 were excluded due to insufficient time elapsed to evaluate impact. The research team contacted stakeholders from 15 countries via email, purposively selected based on the above criteria and geographic representation, to invite them to participate in an interview. Participation was voluntary. Up to three email contacts were made to encourage stakeholders to share their experiences with Optima. Where possible, representatives from a variety of organizations were invited and included, such as National AIDS Programs (NAP) or local equivalent, National TB Programs (NTP), Ministry of Health (MOH), the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

Overall stakeholders from nine countries agreed to participate in the qualitative assessment, representing a total of 11 country contexts: five HIV settings, two TB settings, and two settings in which both HIV and TB analyses were conducted. This includes Belarus, Botswana, Eswatini, Kyrgyzstan, Malawi, Mozambique, Peru, Ukraine, and Zimbabwe (Table 1).

Table 1. Overview of study participants

Country / Region	Disease focus	Number of interviews	Number and type of interview participants		Language of interview(s)
Belarus	TB	2	5	NTP	English/ Russian*
	HIV	1	4	UNAIDS, GF	Russian*
Botswana	HIV	1	3	NAP	English
Eastern Europe and Central Asia	HIV	1	1	GF	English
Eswatini	HIV	1	5	NAP	English
Kyrgyzstan	HIV	1	2	NAP, UNAIDS	English/ Russian*
Latin American and Caribbean	HIV	1	1	GF	English
Malawi	HIV	2	1	MOH [‡]	English
			1	GF	English
	TB	1	4	NTP	English
Mozambique	TB	1	5	MOH	English/ Portuguese*
Peru	TB	1	8	MOH	Spanish [†]
Ukraine	HIV	2	2	MOH	English/ Ukrainian*
			2	UNAIDS	English

Zimbabwe	HIV	1	10	MOH, NAP	English
GF-Global Fund; MOH-Ministry of Health; NAP-National AIDS Program; NTP-National TB Program (or local equivalent)					
* Interpreter present; † Facilitated in Spanish and notes translated; ‡ Technical consultant					

For the purpose of reporting, study participants are only identified by stakeholder group (CS: country stakeholder; IFHO: International funding or health organization representative) to ensure confidentiality.

Data collection procedures

Overall, 16 in-depth small group interviews were held with 45 country stakeholders and nine funding organization and NGO representatives (Table 1). Burnet Institute and World Bank representatives facilitated virtual interviews via the videoconferencing software Zoom using a semi-structured interview guide. Each interview involved between 1 and 10 participants and went for 45-60 minutes. If more key stakeholders were identified or were unavailable in the first interview, a second interview was conducted. Interviews were conducted in English with the exception of Peru, which was led in Spanish. An interpreter assisted in interviews where translation was required. Interviews were audio recorded with verbal consent from participants.

Data analysis

Qualitative data consisted of detailed and analytical notes taken during all interviews supplemented by partial transcriptions. Interview recordings were partially transcribed focusing on informational content except in three interviews impacted by recording error. Qualitative data were coded and sorted inductively using Microsoft Excel. Codes were iteratively refined, and emergent themes were structured around the outcomes of Optima research and determinants of research translation. The coding process was led by the lead author with input from other authors during regular review meetings. The results presented in this manuscript focus on the determinants of modelling evidence being translated into policy and practice.

Public involvement

Participants were not involved in the evaluation design or conduct but were involved in the implementation of the original Optima modelling studies, including priority setting, data collation, result validation and interpretation. A draft version of this manuscript was disseminated to all study participants prior to submission with an opportunity to provide comment on how their experience were represented or opt out of having their data included in the published manuscript. No participants objected to publication. The evaluation findings are also being circulated to participating groups as country case studies and a technical report. The findings of this evaluation will inform public involvement in future Optima modelling studies.

Results

Determinants of research translation

Six major themes were identified that act as facilitators or barriers to implementing modelling findings in policy and financing decisions (Table 1). These determinants of research translation are outlined in

the sections below, describing the circumstances that aid or hinder successful translation of research into policy.

Table 2. Facilitators and barriers of translating modelling evidence into policy identified in the evaluation process

	Facilitator	Either facilitator or barrier	Barrier
Perceived validity of findings	<ul style="list-style-type: none"> ▪ Awareness and understanding of Optima ▪ Familiarity ▪ Findings corroborated global guidance ▪ Extended training 	<ul style="list-style-type: none"> ▪ Local capacity ▪ Alignment with country targets ▪ Data availability and quality 	<ul style="list-style-type: none"> ▪ Skepticism of modelling ▪ Dissatisfaction with choice or handling of data ▪ Results challenged expectations Consequences for health and social equity ▪ Population size uncertainty
Stakeholder engagement	<ul style="list-style-type: none"> ▪ Wide range of stakeholders ▪ Multisectoral engagement ▪ Local ownership ▪ Joint planning ▪ Opportunities for dialogue ▪ Interactive process ▪ Alignment with country needs 	<ul style="list-style-type: none"> ▪ Engagement with policy and program leads 	<ul style="list-style-type: none"> ▪ Insufficient opportunity for feedback ▪ Narrow participation
Engagement with international funding organizations	<ul style="list-style-type: none"> ▪ Key international funding organizations consulted throughout modelling process 	<ul style="list-style-type: none"> ▪ Funder preferences 	<ul style="list-style-type: none"> ▪ Historical allocation patterns ▪ Optima involvement driven by international funding organizations
Timing	<ul style="list-style-type: none"> ▪ Completed prior to key grant applications ▪ Sufficient time allocated 	<ul style="list-style-type: none"> ▪ Data availability at time of analysis ▪ Integration with other modeling and costing exercises 	<ul style="list-style-type: none"> ▪ Finalized too late to inform key strategy or funding organization decisions ▪ Other priorities competing for time and resources
Health system financing	<ul style="list-style-type: none"> ▪ Health system reform ▪ Mechanisms to transfer funds between activities and funding streams 	<ul style="list-style-type: none"> ▪ Influence on budgeting decisions 	<ul style="list-style-type: none"> ▪ Line-item budget systems ▪ Fragmented funding streams
Socio-political and environmental context	<ul style="list-style-type: none"> ▪ Political will 		<ul style="list-style-type: none"> ▪ Sociopolitical unrest ▪ COVID-19 pandemic and response

1. Perceived validity of findings

Stakeholders' **awareness and understanding of Optima** impacted their perceived validity of Optima findings, which subsequently influenced decision making. Stakeholder groups demonstrating good awareness of Optima tended to portray broader acceptance and consideration of Optima recommendations in local policy compared to those with lower understanding of Optima modelling. Participants also highlighted that the awareness and understanding of allocative efficiency among international funding partners was a determinant of research uptake and translation, with interest and engagement in allocative efficiency varying between partners, teams and regions.

Countries which had been involved in multiple Optima analyses or previous HIV Investment Case projects portrayed greater confidence and knowledge of Optima methodology and capabilities. In these cases, **familiarity** with Optima and allocative efficiency had facilitated more meaningful engagement with the processes, including the critical assessment of data inputs and findings, and enabled greater ownership. Some representatives from countries who had only participated in one prior analysis also recognized that their acquired knowledge and familiarity with Optima would support them in future analyses.

“We are now aware of how the model works; it would be good to maintain a working relationship.” (CS1)

Perceived validity of findings was also influenced by accordance of findings with expectations, organizational beliefs and alternative evidence. Where **findings corroborated global guidance** or institutional beliefs, Optima added to a local evidence base and increased motivation for utilizing the findings in resource allocation. For instance, in one country Optima findings provided underlying arguments to support the shift to universal ART access, in line with World Health Organization (WHO) guidance, leading to increases in investment in ART. Conversely, in some settings where **results challenged expectations or beliefs**, the modelling evidence was discounted or not considered for financial decision making. This was often connected to data availability or population size uncertainty, and in some applications the reliance on assumptions or limited data negatively affected the perceived validity of the results. In one setting with pronounced population size uncertainty stakeholders believed that the proportion of new HIV infections among people who inject drugs (PWID) had been overestimated and thus the recommended scale-up of PWID prevention interventions was not justified. Despite commonly reporting involvement in data collation, in select cases respondents communicated **dissatisfaction with the choice or handling of data** used in the model. Perceived validity was also compromised in select examples when there were discrepancies between Optima HIV and epidemiological projections from other HIV epidemiological models used for annual planning and forecasting.

Alignment with country targets and priorities was also an important consideration. In one instance, respondents conveyed that pre-exposure prophylaxis (PrEP) was being scaled up, despite this not being supported by model findings, due to preestablished funding and government priorities. Diverse stakeholders, including program planners, policy makers and donors, emphasized that the policy

environment is increasingly structured around cross-cutting programs, including structural interventions and integrated disease programs.

In some settings respondents conveyed that there was a general **skepticism of modeling** among some personnel involved or key decision-makers, which was not unique to Optima. One country representative explained that evidence generated through modeling was perceived as inferior to empirical data derived from programs or studies. Some stakeholders perceived the process of model calibration to be overly subjective and prone to biases, making these stakeholders doubtful and critical of the outputs.

“When they see the back of it and appreciate that they can play with the figures, then it becomes more [of a] political instrument rather than [an] epidemiological instrument.” (IFHO)

A few means were discussed to strengthen knowledge and awareness of Optima and modeling processes. Most eminently, **extended training and building local capacity** to use Optima were portrayed as a key route to developing local ownership. Although the training provided from Optima was appreciated in many settings, respondents from one country conveyed that no training had been received, and respondents from multiple countries suggested that extended training would have been useful, particularly for technical leads. For example, in one instance five-day training workshops were described as “intensive, yet still not enough” (CS). Based on input from funding organization representatives, conducting training and modeling as part of a collaborative workshop may offer a more immersive experience for participants and facilitate meaningful involvement, dialogue and collaboration.

In some settings, recommendations to deprioritize interventions serving specific population groups or with social and health impacts outside of HIV/TB were reportedly met with resistance among stakeholder groups who represent the needs and service delivery among implicated populations. In these cases, certain modeling outputs may have **consequences for health and social equity**. This lowered the perceived validity of findings among some stakeholders.

“We faced some challenges and resistance while reallocating those funds, specifically on the side of civil societies and NGOs because due to the Optima results, we had to taper off funding from one community and groups towards the others.” (CS2)

2. Stakeholder engagement

Stakeholder selection

The type of stakeholders included in Optima analyses varied by country, but generally involved representatives from the NAP, NTP and/or MOH, as well as potentially NGOs and civil society organizations (CSO), funders, and international organizations. Country partners were encouraged to involve all perceived relevant stakeholders. Country respondents generally appreciated engagement of a **wide range of stakeholders** representing different categories – from technical to policy makers – and including multisectoral representation.

Funding organization and international stakeholder representatives perceived that effective engagement with in-country stakeholders, and particularly the MOH, was integral to fostering **local ownership** of Optima products. In one setting, respondents attributed the lack of ownership to minimal follow up, discussion and influence of Optima results on policy.

Types of participation

Country representatives most commonly reported being engaged in **data collation**. There were fewer examples of country teams that had been directly involved in model calibration and projections. However, country teams that had participated in repeat analyses expressed enthusiasm and knowledge to be more involved in future analyses.

Participants valued meaningful **opportunities for dialogue**, and in isolated cases respondents recalled insufficient opportunity to provide feedback to their country leads, thus limiting the perceived validity and subsequent application of findings.

“I think it’s a matter of discussion and preliminary work with national team – discussion and finding a common ground.” (IFHO)

“We were not able to follow through the whole process because we were not in a position to give feedback to our principles [country leads].” (CS3)

In numerous settings, participation was enhanced through **joint planning** between country partners and the Optima team. Effective joint planning supported **alignment with country needs** by enabling tailored analyses adapted to specific country priorities and required budgeting decisions, such as district-level analyses to support geographical targeting of voluntary male medical circumcision or analyses focusing on the impact of COVID-19 service disruptions.

“It was the NTP that proposed the modelling exercise should be done at district level”. (CS4)

Other characteristics of **effective participation** described by respondents included interactive processes, opportunity to review data inputs and outputs, technical assistance from the Optima team, and consistent follow up.

Stages of involvement

Interview respondents described ways to strengthen participation by engaging stakeholder groups in different ways over the course of Optima study implementation. Engagement of a wide range of stakeholders was considered most important during study set-up and dissemination to facilitate awareness raising, information sharing, contribution to research questions and validation of findings. Multisectoral involvement including NGOs and international stakeholders was perceived as particularly important during **dissemination** to support policy-maker and funder buy-in. For instance, representatives from one participating country emphasized the importance of discussing findings with

ministries outside of health to gain broader support for interventions such as opioid substitution therapy (OST) and to influence national strategy.

Respondents from some settings suggested that **earlier engagement** of some stakeholders, such as funding organization and CSO representatives, could facilitate understanding and support of Optima findings.

“It would be beneficial to include someone from the civil society in this taskforce. If excluded, they might think the government is hiding something or has some sort of hidden agenda. We will gain more support and understanding from them if that person will be included.” (CS2)

Nevertheless, there were differing views on whether **policy and program leads**, including government officials, should be involved earlier and throughout the analysis to promote ownership of findings, or whether engagement with these leads was more useful when restricted to stages such as defining national policy questions and dissemination. Funding organization representatives valued focusing participation on monitoring and evaluation (M&E) personnel to promote Optima as a data-driven technical exercise.

“So the way we organized this we didn’t do the political part. We sold it as a very technical exercise. And we involved people from the M&E departments. There were no decision makers, just the people who do the data, the M&E. So the result was it was a very helpful exercise.....” (IFHO)

3. Funding organization influence

Respondents from several settings identified that **funder preferences** had a bigger influence on resource allocation than Optima findings, although the two were not necessarily exclusionary. In some cases, funder support may have reinforced the scale-up of interventions such as HIV self-testing, which was prioritized in several Optima analyses. In a couple of cases respondents perceived that funders discounted the research findings to comply with their own priorities.

The extent of **funding organization involvement** in Optima analyses was also a determining factor for research translation. Some funding organization representatives acknowledged that where funders exclusively drove Optima implementation, it may have lessened country ownership and reduced the analysis to a requirement for funding applications rather than a tool for decision making. In contrast, in some settings respondents felt that involving all key funders earlier in the Optima process could better support the use of findings for budgeting decisions. Limiting funding organization involvement to a single sitting for dissemination of findings may have inhibited the appreciation and uptake of findings, particularly in settings receiving international funding from multiple entities.

Country representatives and funding organization representatives both relayed that budgets tended to favor **historical allocation patterns**, which limited translation of research findings into policy and financing decisions in some settings.

“Funding for subsequent years would usually be predominantly based on the previous year. So it’s more of a recurrent budget and budget proportions, not necessarily guided by evidence of impact.” (CS1)

4. Timing

The timing of Optima analyses was a key determinant in application of findings. Analyses and dissemination that were **completed prior to key grant applications** or strategic development had opportunity to inform these decision processes. In some cases, strategic planning could still be informed by preliminary findings from the modeling. In other examples, due to delays in model implementation or stakeholder review, unforeseen circumstances, as well as different planning cycles, analyses were **finalized too late to inform key strategy or funding organization decisions**. Both country and funding organization representatives spoke about the importance of factoring in **sufficient time** for preparation, country engagement and data collation.

Timing was also mentioned in relation to **data availability**. Delays in analyses may be caused by waiting for new data, such as updated National AIDS Assessments (NASA) reports. Interviewees found that the timing of analyses should be intentionally aligned to utilize the most recent epidemiological or financial studies.

Competing demands at the time of Optima analyses was a limiting factor for stakeholder engagement. In one example, the Optima application happened simultaneously with the development of the M&E framework for the new National Strategic Plan, thus limiting staff availability to support the Optima analysis. More broadly, funding organization representatives noted that competing priorities and busy agendas, particularly in the context of the COVID-19 pandemic, made it harder for country stakeholders to engage with Optima and had delayed several analyses. In some cases, stakeholders recognized that competing priorities coupled with limited resources increased the perceived value and application of allocative efficiency analyses.

“The issue of allocative efficiency always remains a priority in terms of our response because we don’t have adequate resources and we also do have now quite a number of competing priorities.” (CS3)

Representatives from one participating country raised poor timing of analytical activities due to **inadequate integration of various modeling and costing exercises**. This led to a duplication of effort to track resources and collate data, such as for NASA and National Health Accounts, and Optima and Spectrum.

5. Health system financing mechanisms

In some settings budget reallocations were constrained by the health system financing model. Line-item payment systems define the total amount to be financed to a hospital or other organization based on the expected costs of clinical and non-clinical staff, equipment, medicines, utilities, and maintenance, which are determined based on expenditure in the previous year²¹. Systems that utilized **line-item budgets** to finance in-patient services lacked the flexibility and incentive to transition to ambulatory, decentralized care models, even when Optima findings demonstrated alternatives to be more cost-effective and efficient. Without changing how health services are funded at a structural level, adopting

these changes would lead to reductions in hospital funding in subsequent years. In these cases, the system lacked appropriate **mechanisms to transfer funds**, such that savings could not be reinvested in alternative activities nor for comparable care outside of the hospital setting.

“The number of beds have decreased, but this does not mean that they release the funds...for other activities.” (CS5)

Fragmented funding of epidemic responses also posed challenges to redistribute either existing funding or cost-savings through implementation efficiencies. Respondents from several settings spoke of difficulties to transfer cost savings from general population HIV testing programs to key population prevention and testing due to different sources of program budgets. In one case this meant that while the state budget increased commitments for key population prevention in line with Optima recommendations, eventually these funds were not disbursed due to the complexity in actualizing resource reallocation. Subsequently, **health system reform** was identified as a key enabler of resource allocation in line with cost-effectiveness considerations and specific Optima recommendations.

In one setting, health system reform was underway to reduce the dependency on donor funding, promote sustainability and improve the efficiency and quality of care. This included the introduction of social contracting, enabling public health centers to purchase HIV prevention services through non-government and CSOs. In this example, the respondent felt that making the government the main recipient of international funding gave them more power to advocate to local governments and increase funding for key population programs through social contracting, in line with modelling recommendations. They described this as a lengthy process taking place over two-to-three years which eventually enabled better adoption of allocative efficiency findings.

“So, [local governments] begin to see the benefits of these expenditures now as well as the purpose of it. Thus it is much easier to convince them now that funding for these areas should be increased. So, the role of the main recipient as a main driving force in advocating state social contracting is very strong.” (CS7)

Optima commonly engages most closely with the NAP and NTP for HIV and TB studies, respectively. Some respondents referred to these parties having **limited influence on budget** decision making. Their actions were constrained to making recommendations to the relevant government structure, but this was insufficient to enable the translation of Optima findings to resource allocation in some settings.

“The NTP is not the owner of the government funds. It has limited influence on how the funds are allocated.” (CS5)

The impact of **indirect spending** such as management costs and overheads for the national HIV program cannot be readily quantified in terms of direct impact on defined disease transmission parameters and are usually considered as a fixed expense in Optima allocative efficiency analyses. In practice, country teams often found it difficult to differentiate direct from indirect spending. Some respondents reported a need to better understand indirect spending, such as administrative costs and supply chain management, to inform resource allocation.

“The performance of a program depends on various factors, which I believe need to be included in future modelling to bring robust results...For instance, we have a shortage of human resources – it’s one of the determinants of the performance.” (CS6)

6. Socio-political and environmental context

Respondents considered that **political will** was important when findings concerned key population groups or migrants, which were politically sensitive in some contexts. In settings where related behaviors are criminalized or these groups are not prioritized in existing resource allocation, Optima findings were more likely to face resistance from policy makers, particularly outside of the NAP or NTP or at a sub-national level. This was particularly pertinent in settings in the process of **transitioning from international to domestic spending**.

“A governor in a region may have never heard before how MSM are influencing pandemics and now he is told that funds need to be allocated for condoms for this group, for lubricants. Usually, these things come as a shock to local government.” (CS7)

Despite the expected resistance in these settings, funders perceived that Optima supported advocacy by providing objective rationale for prevention programs for key populations. Optima provides an opportunity to “put the science before the politics” (IFHO), and in this way has the potential to depoliticize resource allocation.

External factors such as **socio-political unrest** and the COVID-19 pandemic also impacted the influence of Optima findings on resource allocation. In one setting, conflict and the existence of autonomous regions meant that sub-national HIV programs and services are not controlled or funded by the Government, and thus not influenced by Government resource reallocations. The **COVID-19 pandemic** has affected access and uptake of HIV and TB services globally through lockdowns and stay-at-home orders, physical distancing requirements, reluctance to access services due to fear of infection, disruptions to public transportation, reduced services, staff shortages, and changes in health communication.²² The strain on health services and infection risk have necessitated adaptive measures for service provision²² which were not factored into pre-pandemic Optima analyses and may affect the relevance of Optima recommendations today. In addition, the COVID-19 pandemic placed strain on healthcare resources and budgets, necessitating diversion of funds from other health programs.

“Every free cent was reallocated to COVID.” (CS8)


“The concept of efficiency was not high on the agenda. The other problems they are facing, in their view, are more important. No human capacity or time to focus.” (IFHO)

In some settings, respondents reported increases in service costs due to COVID-19, further impacting the relevance of prior allocative efficiency analyses.

Outcomes of Optima applications

Country stakeholders and funding organization representatives conveyed that Optima HIV and TB analyses have led to a range of outcomes which can be broadly grouped as immediate, intermediate, and longer-term outcomes. These respectively correspond to outcomes improving understanding, those supporting planning, and those influencing implementation, summarized in Figure 1.

Figure 1. Overview of outcomes reported from involvement in Optima HIV and TB analyses



Although longer-term outcomes have greater significance to cost-effecting programming and ability to impact epidemic measures, many respondents also acknowledged the value of the more immediate outcomes such as generating internal dialogue and strategic thinking on programs, priority populations, and data gaps.

"The exchange of the results of this modeling – what works, what doesn't work, what data we have...catalyzes internal discussions about the quality of data and the completeness of data." (IFHO)

The most common application of Optima HIV and TB analyses reported by interview respondents was to inform grant proposals and strategy documents. The timing of Optima analyses was often tied to Global Fund funding requests, and Global Fund grants were most frequently cited as having been informed by Optima. Specifically, respondents referred to using Optima findings to help set targets, select high-impact and cost-effective activities, and plan budgets. This was corroborated in publicly available grant proposals. Some respondents referred to using Optima findings to support advocacy for new investments, such as changes to modalities for testing and treatment delivery.

"With Optima study, we can really see where we can negotiate or request funding. [By] showing evidence that by doing this and that intervention we can really have more impact and help the [HIV] program" (CS6)

“As a country I think we did benefit in terms of the exercise because it opened our eyes in terms of the different programs where we need to prioritize as a country; where we can spend less and get more from” (CS9)

A representative from a IFHO described how Optima had provided supporting evidence for ongoing advocacy efforts to reduce the price of antiretrovirals, given differential pricing made obvious through a regional Optima exercise.

Funding organization representatives in particular considered that Optima provided an objective basis for policy advocacy, which was particularly useful when results supported increased funding for programs not readily supported by the government agenda. For instance, in one country Optima findings were actively used in discussion with government bodies to scale-up OST, helping to overcome legislative barriers to OST prescription and gain support for OST both within and external to health departments. Despite there being considerable existing evidence supporting interventions such as OST or universal ART, stakeholders valued the ability of Optima to provide localized evidence.

“The biggest breakthrough in our case was with opioid substitution therapy. In 2018 the expenditures were at US\$ 103k, while in 2022 they committed US\$ 800k with an increase to US\$ 825K in 2024.” (CS7)

Discussion

This evaluation confirmed there are a multitude of factors influencing the use of modelling to guide national HIV and TB programs. Allocative efficiency modelling has a supportive role in opening dialogue around budget allocations and providing localized evidence to support planning and advocate for funding. Facilitating stakeholder engagement and collaboration between policymakers and researchers can help to bridge modelling evidence, policy and practice for greater impact in achieving health outcomes.

Although modelling was not always attributed with providing new evidence, this evaluation showed that the triangulation of empirical evidence and global guidance with localized modelling can enhance acceptance and adoption of evidence-informed practices. Modelling findings were frequently cited as consistent with resource allocations designated within funding proposals and strategic planning. While some respondents supported the role of Optima in these decisions, other research has reported on modelling evidence being used symbolically to support existing decisions and strategy.¹⁵ International funding organizations, government bodies, and public health researchers may have preconceived notions or agendas leading to confirmation bias. Conversely, findings that contradicted stakeholders’ beliefs were, at times, rejected. This may be particularly important for programs that may be politically polarizing, such as those serving key populations.


Findings demonstrated higher perceived value of modelling among stakeholders when it was built around country priorities, timing of policy decision-making, and the broader health system context. Consistent with other studies, we found that international funding organizations often initiate the analyses or define the modelling objectives.¹⁶ Funding organizations may have a narrower focus than national disease or health programmes,²³ which may limit the perceived usefulness and national uptake of findings. Both national and international stakeholders conveyed a need for modelling to support

integrated disease and program delivery, structural interventions, and decisions around human resources and program administration. By not accounting for these, disease-specific models may not fully capture operational feasibility and decision-making processes, thus undermining perceived validity.²⁴ Multi-disease, “whole system” approaches which consider interactions between diseases, interventions and the health system, such as for the Thanzi La Onse model in Malawi, may enhance the relevance of modelling for local decision-making and resource allocation.^{25,26} Further modelling which considers the workforce capacity and subsequent costs will facilitate transparent and feasible estimates of providing cost-effective interventions.

The realization of resource allocation in line with allocative efficiency is dependent on the flexibility of funding within a health system, particularly whether funds can be reallocated between programs. Financing for key populations prevention programs is frequently still provided by international funders through CSOs, while domestic funding often covers care and treatment. The evaluation findings demonstrates that this fragmented investment approach was often a barrier to redistributing funding from generalized testing and prevention to programs focusing on key populations. Many countries dependent on external funding are graduating to domestic funding in the near future.²⁷ Mapping of the responsible funders and their recipients, expenditures, coverage, and consequential impact of all programs through modelling allows for an evidence-informed list of interventions that could be prioritized by local governments. Social contracting is one proposed mechanism to promote the strengths and sustainability of CSOs’ role in tailoring HIV and TB services towards the needs of those most vulnerable. It involves governments contracting CSOs to delivery services to key populations, thus channeling government financing for community-based outreach and care initiatives.²⁸ A 2021 study analyzing the sustainability of CSO provided services in the Eastern European and Central Asian region found that these services, often provided by peers for those most marginalized, are slow to be financed by local governments,²⁹ which was also demonstrated in this analysis. Collaborative modelling exercises can support the implementation of social contracting by engaging partners in constructive dialogue and consensus building on target setting and budget allocation.³⁰

In practice, interviewees described a wide spectrum of stakeholder participation in Optima analyses. These findings are consistent with the International Association for Public Participation (IAP2) spectrum,³¹ which considers multiple ways to engage stakeholders in research to inform government decision making (Figure 2). This is also supported by a study looking at research translation from mathematical models of vaccine-preventable diseases,¹⁵ suggesting these findings may be broadly applicable beyond Optima HIV and TB models. Where models are not institutionalized at a national level, additional funding may be needed to support remuneration and mobilize appropriate national consultants and teams to engage in the modelling process. In addition to broader engagement, the timing of engagement throughout the modelling process can determine alignment with policy makers’ needs and priorities. Appropriate information exchange at the start of a study can help to familiarize stakeholders with modelling processes, needs and limitations in order to set realistic expectations and promote transparency. As the model is detailed, engagement helps to identify constraints to changing policy, financing and practice, set realistic assumptions and contextually achievable scale-up targets and accommodate equity needs. After developing mathematical modelling evidence based on cost-effectiveness, engagement allows stakeholders to advise on the communication of results and equity concerns that could arise from proposed reallocation of resources away from specific population groups.^{32,33}

Figure 2. Levels of stakeholder participation in Optima research applied to the research-modified International Association for Public Participation (IAP2) spectrum ³¹, International Association for Public Participation (www.iap2.org)



To maximize relevance to policy and target setting, the timing of analyses should be planned to allow sufficient time for study set up and data collation, buffer potential delays, accommodate sufficient time for stakeholder communication and collaboration, and ensure completion before key strategic planning and grant proposals. We found that utilizing workshops can facilitate direct engagement, collaboration and effective communication between modelers and stakeholders and empower relevant stakeholders to use and interpret modelling. Findings also demonstrated the value of repeat applications of modelling to build on local capacity and support local leadership in applying modelling to HIV and TB program decision making. Further, repeat modelling, which was more common in the context of HIV, can drive data collection and availability. However, high turnover of personnel in some positions may potentially be a barrier to building institutional capacity and familiarity with modelling.

A number of limitations should be considered when interpreting these findings. The results may not represent the views of institutions and individuals who were non-responsive to multiple interview requests, and thus biased to settings with higher engagement in Optima processes or a more recent Optima analysis. High departmental staff turnover and secondment from HIV/TB to COVID-19 may have

also impacted participation. Interviews were facilitated by the Optima research team with the potential to introduce social desirability bias. However, the interviewers encouraged honest feedback and participants relayed both positive and negative experiences and outcomes. This evaluation focused on country stakeholders and funding organizations as key consumers of Optima research, with limited input from international health organizations. Findings may not be generalizable to other entities utilizing modelling evidence, such as WHO and UNAIDS.

In conclusion, this evaluation demonstrates that allocative efficiency modeling has supported evidence-informed decision making in numerous contexts, enhanced the conceptual and practical understanding of allocative efficiency and supported constructive dialogue on the data and evidence. These findings have relevance to diverse modelling groups informing health program and financial planning in international contexts. To facilitate the translation of modelling results into policy and practice, modelling collaborators should time analyses prior to key strategic and financial planning exercises, involve diverse stakeholders at key stages, and enable familiarity and understanding of the model. To further improve relevance and acceptance of modelling findings, there needs to be greater consideration given to integrated disease modelling, equity goals, and financing constraints.

Footnotes

Acknowledgements: The Burnet Institute and the World Bank are grateful for all feedback provided by participants from country teams and from international partners and acknowledge the founding work of all personnel and collaborators who provided input on the original Optima analyses. The team extend their gratitude to Anna Roberts for support with project administration and data collection, to Jaime Nicolas Bayona Garcia, Roman Kulchynskiy and Felix Tsoy for providing translation support during interviews, and to Nisaa Wulan and Lung Vu for their contributions to the analyses and interpretation.

Contributors: The evaluation was conceptualized and planned by NFH, NC, NS, DtB, and RMH. Data collection was carried out by DtB, NFH, ALB and RMH. Data analysis was led by AB with support from DtB. Manuscript writing was led by ALB. All authors contributed to the interpretation of the data, manuscript review and editing. NS is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: This work was funded by the World Bank, who contributed to study design, implementation, analysis, interpretation and manuscript review. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.

Competing interests: The authors have no competing interests to declare relating to this work.

Ethics approval: The original QA exercise was not subject to ethics review. The Alfred Hospital Ethics Review Committee approved the collation and analysis of the program QA data (project number:158/22). All study participants were notified of the use of their data for extended research purposes and had the opportunity to opt out of further research.

Data availability: Data from this evaluation is not available for sharing as per ethics agreements. Data and reports for underlying country models are published and openly available in the World Bank Open Knowledge Repository (<https://openknowledge.worldbank.org/>) and through Optima (<http://optimamodel.com/>).

References

1. UNAIDS. Global AIDS Update 2018: Miles to go. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2018. Available from: https://www.unaids.org/en/20180718_GR2018.
2. Transforming our world: the 2030 Agenda for Sustainable Development: United Nations Department of Economic and Social Affairs; 2015.
3. UNAIDS. Understanding Fast-Track: accelerating action to end the AIDS epidemic by 2030 2015 [cited 2022 Jan 28]. Available from: https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf.
4. The HIV Financial Dashboard: UNAIDS; [cited 2022 Jan 20]. Available from: <https://hivfinancial.unaids.org/>.
5. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Available from: <https://www.who.int/publications/digital/global-tuberculosis-report-2021>.
6. World Health Organization. The End TB Strategy. Geneva: WHO; 2015 [cited 2022 Feb 15]. Available from: <https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy>.
7. Kurowski C, Evans DB, Tandon A, Eozenou PH-V, Schmidt M, Irwin A, et al. From Double Shock to Double Recovery : Implications and Options for Health Financing in the Time of COVID-19. Health, Nutrition and Population Discussion Paper. Washington, DC: World Bank; 2021. License: CC BY 3.0 IGO. Available from: <https://openknowledge.worldbank.org/handle/10986/35298>
8. Mahy M, Marsh K, Sabin K, Wanyeki I, Daher J, Ghys PD. HIV estimates through 2018: data for decision-making. *Aids*. 2019;33 Suppl 3(Suppl 3):S203-s11.
9. Sweileh WM. Global research activity on mathematical modeling of transmission and control of 23 selected infectious disease outbreak. *Globalization and Health*. 2022;18(1):4.
10. McBryde ES, Meehan MT, Adegboye OA, Adekunle AI, Caldwell JM, Pak A, et al. Role of modelling in COVID-19 policy development. *Paediatr Respir Rev*. 2020;35:57-60.
11. Goscé L, Abou Jaoude GJ, Kedziora DJ, Benedikt C, Hussain A, Jarvis S, et al. Optima TB: A tool to help optimally allocate tuberculosis spending. *PLoS Comput Biol*. 2021;17(9):e1009255.
12. Kelly SL, Martin-Hughes R, Stuart RM, Yap XF, Kedziora DJ, Grantham KL, et al. The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS. *The Lancet HIV*. 2018;5(4):e190-e8.
13. Kerr CC, Stuart RM, Gray RT, Shattock AJ, Fraser-Hurt N, Benedikt C, et al. Optima: A Model for HIV Epidemic Analysis, Program Prioritization, and Resource Optimization. *J Acquir Immune Defic Syndr*. 2015;69(3):365-76.
14. Stover J, Glaubius R, Kassarjee R, Dugdale CM. Updates to the Spectrum/AIM model for the UNAIDS 2020 HIV estimates. *Journal of the International AIDS Society*. 2021;24(S5):e25778.
15. Christen P, Conteh L. How are mathematical models and results from mathematical models of vaccine-preventable diseases used, or not, by global health organisations? *BMJ Global Health*. 2021;6(9):e006827.
16. Revill P, Rangaraj A, Makochekeka A, Mpofu A, Ciaranello AL, Jahn A, et al. Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa. *The Lancet HIV*. 2022.
17. Thompson J, McClure R, Blakely T, Wilson N, Baker MG, Wijnands JS, et al. Modelling SARS-CoV-2 disease progression in Australia and New Zealand: an account of an agent-based approach to support public health decision-making. *Australian and New Zealand Journal of Public Health*. 2022;46(3):292-303.

18. Delva W, Wilson DP, Abu-Raddad L, Gorgens M, Wilson D, Hallett TB, et al. HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation. *PLoS Med.* 2012;9(7):e1001239.
19. Behrend MR, Basáñez M-G, Hamley JID, Porco TC, Stolk WA, Walker M, et al. Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium. *PLOS Neglected Tropical Diseases.* 2020;14(4):e0008033.
20. Lasry A, Richter A, Lutscher F. Recommendations for increasing the use of HIV/AIDS resource allocation models. *BMC public health.* 2009;9 Suppl 1(Suppl 1):S8-S.
21. World Health Organization Regional Office for Europe. A people-centred model of TB Care: Blueprint for EECA countries, first edition: World Health Organization; 2017 [cited 2021 January 10]. Available from: <https://www.euro.who.int/en/health-topics/communicable-diseases/tuberculosis/publications/2017/a-people-centred-model-of-tb-care-2017>.
22. The Global Fund. The impact of COVID-19 on HIV, TB and malaria services and systems for health: a snapshot from 502 health facilities across Africa and Asia. Geneva: The Global Fund; 2021.
23. Biesma RG, Brugha R, Harmer A, Walsh A, Spicer N, Walt G. The effects of global health initiatives on country health systems: a review of the evidence from HIV/AIDS control. *Health Policy and Planning.* 2009;24(4):239-52.
24. Avanceña ALV, Hutton DW. Optimization Models for HIV/AIDS Resource Allocation: A Systematic Review. *Value Health.* 2020;23(11):1509-21.
25. Revill P, Rollinger A, Richards S. Thanzi la Onse 2021 Annual Report: Thanzi la Onse; 2021 [cited 2022 Jul 26]. Available from: <https://thanzi.org/wp-content/uploads/Thanzi-la-Onse-Programme-Report-2021.pdf>.
26. Thanzi La Onse (TLO): HIV Modelling Consortium, Institute for Global Health, UCL; [cited 2022 Jul 26]. Available from: <http://hivmodeling.org/model-database/thanzi-la-onse-tlo>.
27. Micah AE, Su Y, Bachmeier SD, Chapin A, Cogswell IE, Crosby SW, et al. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. *The Lancet.* 2020;396(10252):693-724.
28. The Global Fund. Focus on sustainability, transition and co-financing: The Global Fund; 2017 [cited 2022 Aug 2]. Available from: https://www.theglobalfund.org/media/8467/publication_sustainabilitytransitioncofinancing_focuson_en.pdf.
29. Sustainability of CSO provided HIV and TB Services During and After Transition in East Europe and Central Asia Region: Final report: South Eastern Europe Regional TB and HIV Community Network; 2021 [cited 2022 Jul 29]. Available from: <https://www.seercn.org/uimages/publications/Regional20survey20report20-20SEE20RCN.pdf>.
30. Pudpong N, Viriyathorn S, Wanwong Y, Witthayapipopsakul W, Wangbanjongkun W, Patcharanarumol W, et al. Public contracting with civil society organizations for HIV/AIDS service provisions: A key strategy to ending AIDS in Thailand. *Journal of HIV/AIDS & Social Services.* 2021;20(4):285-301.
31. Bammer G. Key issues in co-creation with stakeholders when research problems are complex. *Evidence & Policy: A Journal of Research, Debate and Practice.* 2019;15(3):423-35.
32. Kaplan EH, Merson MH. Allocating HIV-prevention resources: balancing efficiency and equity. *Am J Public Health.* 2002;92(12):1905-7.
33. Stuart RM, Haghparast-Bidgoli H, Panovska-Griffiths J, Grobicki L, Skordis J, Kerr CC, et al. Applying the 'no-one worse off' criterion to design Pareto efficient HIV responses in Sudan and Togo. *Aids.* 2019;33(7):1247-52.